Sabra Health Care REIT (SBRA) Q4 2025 earnings review
Growth Engine Ignites: Investments Accelerate as Margins Expand
Sabra closed 2025 with a pivot from stabilization to offense. Normalized AFFO grew 4% YoY to $0.38/share, meeting expectations, while the Managed Senior Housing portfolio delivered breakout performance with margins hitting 29.2% (up from 27.5% a year ago). The real story is the capital deployment machine waking up: $150M invested in Q4 and another $240M awarded for early 2026 at attractive ~8% yields. With leverage stabilized at 5.0x and 2026 guidance pointing to ~5% AFFO growth, Sabra is aggressively capitalizing on the senior housing cycle.
🐂 Bull Case
Operational leverage is kicking in. Senior Housing - Managed Cash NOI margins expanded to 29.2% in Q4 from 27.5% a year ago, driven by a 150bps occupancy gain to 84.8%. This segment grew Cash NOI 12.6% YoY.
After years of portfolio pruning, Sabra is buying. With $450M closed in 2025 and $240M already awarded for early 2026 at ~8.0% yields, external growth is becoming a primary driver.
🐻 Bear Case
Despite diversification efforts, Skilled Nursing still accounts for 47.8% of Annualized Cash NOI. This maintains high exposure to government reimbursement risks compared to pure-play senior housing peers.
While the managed portfolio is surging, the Triple-Net portfolio (60%+ of NOI) is guided for only 'low-single-digit' Cash NOI growth in 2026, acting as a governor on total portfolio acceleration.
⚖️ Verdict: 🟢
Bullish. Sabra has successfully transitioned from defense to offense. The combination of 5% guided earnings growth, expanding senior housing margins, and a funded pipeline of accretive acquisitions at 8% yields makes for a compelling setup.
Key Themes
Managed Senior Housing Profitability Surge
Accelerating. The Senior Housing - Managed segment is outperforming. Cash NOI Margin expanded sequentially from 28.3% in Q3 to 29.2% in Q4. Occupancy climbed to 84.8%, up from 83.5% a year ago. This operational leverage is the key internal growth engine, fueling a 12.6% YoY increase in same-property Cash NOI.
Investment Activity Ramping Up
Accelerating. Sabra closed $150.5M in investments in Q4 alone (7.0% yield), bringing the FY25 total to ~$450M. Crucially, the forward pipeline is robust: $240M in 'awarded' deals with an estimated 8.0% yield are queued for H1 2026 closure. This marks a definitive shift from net seller to net buyer.
Balance Sheet Stability
Stable. Net Debt to Adjusted EBITDA held firm at 5.00x, exactly on target. With $1.2B in liquidity (including ATM forwards and revolver capacity), Sabra has the dry powder to fund its $240M pipeline without stressing credit metrics. S&P/Fitch rated BBB- (Stable).
Triple-Net Growth Lag
Decelerating. While the managed portfolio is booming, the core Triple-Net portfolio (Skilled Nursing etc.) is essentially a bond proxy. FY26 guidance assumes only 'low-single-digit' Cash NOI growth for this segment. While coverage is healthy (SNF at 2.38x), this segment acts as a drag on total portfolio growth rates.
Disposition Revenue Drag
Stable. Sabra disposed of seven skilled nursing facilities for $51M in Q4. While this prunes the portfolio, the release explicitly notes Sabra 'did not recognize any rent or income related to these facilities in 2025.' This creates a slight near-term headwind to top-line growth as capital is recycled.
Tenant Concentration
Stable. Significant exposure remains to top tenants. The Ensign Group accounts for 7.8% of Annualized Cash NOI, and Avamere is 7.7%. While these are strong operators, any idiosyncratic risk with a top-3 tenant would materially impact results.
Labor Stability
Positive. Management commentary in recent quarters and current margin expansion suggests the labor crisis is largely resolved. Expense control in the managed portfolio is allowing revenue gains to drop to the bottom line.
Other KPIs
Stable. Flat sequentially vs Q3 ($0.38) and Q2 ($0.38), but up 5.5% YoY from $0.36 in 24Q4. The stability in H2 2025 sets a higher floor for 2026 growth.
Accelerating. Increased 50% YoY (from $21.1M in 24Q4) and 25% sequentially (from $25.3M in 25Q3, though seasonality plays a role). This segment is rapidly becoming the primary growth lever.
Improving. Coverage ticked up from 2.35x in Q3 and 2.27x in Q2. This provides significant cushion against potential reimbursement headwinds or tenant struggles.
Guidance
Accelerating. The midpoint of $1.57 implies ~5.4% YoY growth from FY25's $1.49. This acceleration reflects the layering in of Q4 acquisitions and the anticipated closing of the $240M pipeline.
Stable. Maintaining a high growth rate expectation. After achieving 12.6% growth in Q4 2025, guiding for continued double-digit growth confirms the multi-year recovery thesis is intact.
Accelerating. Guidance states they expect to 'exceed 2025's investment total' (which was ~$450M). With $240M already awarded for H1, this target appears conservative and achievable.
Key Questions
Pipeline Pricing Power
The $240M in awarded investments has an estimated 8.0% yield, higher than the 7.0% yield on Q4 closed deals. Is this yield expansion structural, or mix-dependent (e.g., more skilled nursing vs. senior housing)?
Senior Housing Occupancy Runway
Occupancy is at 84.8%. Pre-pandemic levels were often higher (88-90%). How much of the 2026 'low to mid-teens' NOI growth guidance relies on occupancy gains vs. rate growth?
Disposition Strategy
With 7 SNFs sold in Q4, are there further large tranches of non-core asset sales planned for 2026 that might create earnings drag before capital is redeployed?